ECL Stock Recent News
ECL LATEST HEADLINES
Robust segmental performances are likely to have driven ECL's performance in the fourth quarter.
Besides Wall Street's top -and-bottom-line estimates for Ecolab (ECL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
ECL continues to gain from its robust product portfolio and strong segmental performance.
Ecolab (ECL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record of doing well for their share holders.
ST. PAUL, Minn.--(BUSINESS WIRE)--Ecolab will host a live webcast to discuss its 2024 fourth quarter results. A news release containing fourth quarter results is expected to be issued before market open on February 11, 2025. Details for the public webcast are as follows: TIME: 1:00 p.m. Eastern Time DATE: Tuesday, February 11, 2025 DURATION: One hour LOCATION: www.ecolab.com/investor ARCHIVE: A replay of the webcast and supplemental data will be available on Ecolab's website. About Ecolab A tru.
Dividend Aristocrats are stocks on the S&P 500 that have raised their dividends every year for 25 years or more.
Ecolab (ECL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Ecolab (ECL) could produce exceptional returns because of its solid growth attributes.